Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neovasculgen in Painful Bladder Syndrome/Interstitial Cystitis
NCT07391306Phase 3Recruiting
- Sponsor
- NextGen
- Start
- Feb 2024
- Primary completion
- May 2027
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 1
01
Overview
A Phase 3 trial of neovasculgen in interstitial cystitis (IC), sponsored by NextGen. Started Feb 2024; status: recruiting.
02
Drugs
neovasculgen
03
Conditions
interstitial cystitis (IC)
Beyond the preview
Go deeper on NCT07391306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07391306.